![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1662765
ÀǾàǰ¿ë ¸®ÆÛ ÄÁÅ×ÀÌ³Ê ½ÃÀå ¿¹Ãø( -2030³â) : Á¦Ç° À¯Çüº°, ÄÁÅ×ÀÌ³Ê »çÀÌÁ, ±â¼úº°, ¿î¼Û ¼ö´Üº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° ¼¼°è ºÐ¼®Reefer Container for Pharmaceutical Market Forecasts to 2030 - Global Analysis By Product Type, Container Size, Technology, Mode of Transport, Application, End User and By Geography |
Stratistics MRC¿¡ µû¸£¸é, ÀǾàǰ¿ë ¸®ÆÛ ÄÁÅ×ÀÌ³Ê ¼¼°è ½ÃÀåÀº 2024³â 58¾ï 1,000¸¸ ´Þ·¯·Î ¿¹Ãø ±â°£ µ¿¾È ¿¬Æò±Õ 10.1%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 103¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀǾàǰ¿ë ¸®ÆÛ ÄÁÅ×À̳ʴ ¹é½Å, »ý¹°ÇÐÀû Á¦Á¦, ƯÁ¤ ÀǾàǰ µî ¿Âµµ¿¡ ¹Î°¨ÇÑ ÀǾàǰÀ» ¿î¼ÛÇÏ´Â µ¿¾È Á¦¾îµÈ ¿Âµµ ȯ°æÀ» À¯ÁöÇϵµ·Ï ¼³°èµÈ Àü¿ë ³ÃÀå ¿î¼Û ÄÁÅ×À̳ÊÀÔ´Ï´Ù. ÀÌ ÄÁÅ×À̳ʿ¡´Â ÷´Ü ³Ã°¢ ½Ã½ºÅÛÀÌ ÀåÂøµÇ¾î ÀÖ¾î Á¦Ç°ÀÌ Æ¯Á¤ ¿Âµµ ¹üÀ§ ³»¿¡ À¯ÁöµÇ¾î À¯È¿¼º°ú ¾ÈÀü¼ºÀ» À¯ÁöÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. ¸®ÆÛ ÄÁÅ×À̳ʴ ÄݵåüÀÎ ¹°·ù¿¡¼ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, »ý»ê ½Ã¼³¿¡¼ Àü ¼¼°è À¯Åë °ÅÁ¡±îÁö ÀǾàǰÀÇ ¹«°á¼ºÀ» º¸ÀåÇÕ´Ï´Ù.
¹ÙÀÌ¿ÀÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡
´ÜŬ·ÐÇ×ü, À¯ÀüÀÚ Ä¡·áÁ¦, ¹é½Å°ú °°Àº ¹ÙÀÌ¿ÀÀǾàǰÀº ¾ÈÁ¤¼º°ú È¿´ÉÀ» À¯ÁöÇϱâ À§ÇØ ¾ö°ÝÇÑ ¿Âµµ °ü¸®°¡ ÇÊ¿äÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Ã·´Ü Ä¡·á¹ýÀÌ Æ¯È÷ Á¾¾çÇÐ ¹× ¸¸¼ºÁúȯ °ü¸® ºÐ¾ß¿¡¼ ³Î¸® º¸±ÞµÊ¿¡ µû¶ó ½Å·ÚÇÒ ¼ö ÀÖ´Â ÄݵåüÀÎ ¹°·ùÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸®ÆÛ ÄÁÅ×À̳ʴ ÀÌ·¯ÇÑ ¼¶¼¼ÇÑ Á¦Ç°ÀÇ ¿î¼Û¿¡ ÇʼöÀûÀ̸ç, ¿î¼Û Áß¿¡µµ ÇÊ¿äÇÑ ¿Âµµ ¹üÀ§¸¦ À¯ÁöÇÒ ¼ö ÀÖµµ·Ï º¸ÀåÇÕ´Ï´Ù. ¹ÙÀÌ¿ÀÀǾàǰ¿¡ ´ëÇÑ ÀÌ·¯ÇÑ ¼ö¿ä Áõ°¡´Â ¿Âµµ Á¦¾î ¿î¼Û ¼Ö·ç¼Ç¿¡ ´ëÇÑ ÅõÀÚ Áõ°¡¸¦ ÃËÁøÇϰí È¿°úÀûÀÎ ÄݵåüÀÎ °ü¸®ÀÇ Á߿伺À» °Á¶Çϰí ÀÖ½À´Ï´Ù.
¿Âµµ º¯µ¿ À§Çè
Àν¶¸°, »ý¹°ÇÐÀû Á¦Á¦, ¿¹¹æÁ¢Á¾ µî ¿Âµµ¿¡ ¹Î°¨ÇÑ ÀǾàǰÀÇ Ç°Áú°ú È¿´ÉÀº ÇÊ¿äÇÑ ¿Âµµ ¹üÀ§¿¡¼ Á¶±ÝÀÌ¶óµµ ¹þ¾î³ª¸é À§Çè¿¡ óÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿î¼Û Áß ¿Âµµ ºÒ¾ÈÁ¤Àº Àåºñ °íÀå, ´Ü¿ ºÎÁ·, ¿ÜºÎ ȯ°æ µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À§ÇèÀº Á¤È®ÇÑ ¿Âµµ °ü¸®¸¦ º¸ÀåÇϱâ À§ÇØ Ã·´Ü ¸ð´ÏÅ͸µ ½Ã½ºÅÛ, Á¤±âÀûÀÎ À¯Áöº¸¼ö ¹× ½Ç½Ã°£ ÃßÀûÀÇ Á߿伺À» °Á¶ÇÕ´Ï´Ù. ¿Âµµ ¹«°á¼ºÀÌ ¼Õ»óµÇ¸é °í°¡ÀÇ Á¦Ç° ȸ¼ö, ºê·£µå ÆòÆÇ ÀúÇÏ, ¹ýÀû ó¹ú·Î À̾îÁú ¼ö Àֱ⠶§¹®¿¡ ½Å·ÚÇÒ ¼ö ÀÖ´Â ÄݵåüÀÎ ¿î¿µÀÌ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.
ÄݵåüÀÎ ¹°·ù¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.
ÄݵåüÀÎ ¹°·ù¿¡ ´ëÇÑ Áö½ÄÀÇ Áõ°¡´Â ÀǾàǰ ³Ãµ¿ ÄÁÅ×ÀÌ³Ê »ê¾÷ÀÇ ¼ºÀå¿¡ Å« ÈûÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¹é½Å, »ý¹°ÇÐÀû Á¦Á¦, ±âŸ »ý¹° À¯·¡ Á¦Ç° µî ¿Âµµ¿¡ ¹Î°¨ÇÑ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Àü ¼¼°èÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó °ø±Þ¸Á Àü¹Ý¿¡ °ÉÃÄ ÀǾàǰÀÇ ¹«°á¼ºÀ» À¯ÁöÇÏ´Â °ÍÀÌ Á¡Á¡ ´õ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. È¿À²ÀûÀÎ ÄݵåüÀÎ °ü¸®¸¦ ÅëÇØ ¿Âµµ¿¡ ¹Î°¨ÇÑ Ç°¸ñÀ» ÁöÁ¤µÈ ¹üÀ§ ³»·Î À¯ÁöÇÔÀ¸·Î½á Á¦Ç° º¯ÁúÀ» ¹æÁöÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸®ÆÛ ÄÁÅ×ÀÌ³Ê ¹× ¿Âµµ Á¦¾î ¿î¼Û ¿É¼Ç¿¡ ´ëÇÑ ÁöÃâ Áõ°¡, °ÈµÈ ±ÔÁ¦, º¸´Ù ¾ÈÀüÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â ÀǾàǰ¿¡ ´ëÇÑ ¼ÒºñÀÚ ¼ö¿ä Áõ°¡·Î ÀÎÇØ °ø±Þ¸ÁÀÇ Àü¹ÝÀûÀÎ È¿À²¼º°ú ½Å·Ú¼ºÀÌ Çâ»óµÇ°í ÀÖ½À´Ï´Ù.
Àü¿ë ÄÁÅ×À̳ÊÀÇ Á¦ÇÑµÈ °¡¿ë¼º
Á¦¾à »ê¾÷Àº ƯÈ÷ ¿Âµµ Á¦¾î ¿î¼ÛÀÇ Çʿ伺ÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Àü¿ë ³Ãµ¿ ÄÁÅ×À̳ÊÀÇ °ø±ÞÀÌ Á¦ÇÑÀûÀ̶ó´Â Àå¾Ö¹°ÀÌ ÀÖ½À´Ï´Ù. ¸¹Àº ³Ãµ¿ ÄÁÅ×À̳ʰ¡ ¹ü¿ëÀûÀ¸·Î »ý»êµÇ°í ÀÖÀ½¿¡µµ ºÒ±¸Çϰí Ç¥ÁØ ³Ãµ¿ ÄÁÅ×À̳ʴ ÀǾàǰÀÇ °íµµ·Î Ư¼öÇÑ ¿Âµµ ¹× ½Àµµ ¿ä±¸ »çÇ×À» ÃæÁ·½Ãų ¼ö ÀÖ´Â °ÍÀº ¾Æ´Õ´Ï´Ù. ÀÌ·¯ÇÑ Æ¯¼ö ÄÁÅ×À̳ÊÀÇ ºÎÁ·À¸·Î ÀÎÇÑ °ø±Þ¸Á º´¸ñ Çö»ó, Áö¿¬ ¹× Ãß°¡ ºñ¿ëÀ¸·Î ÀÎÇØ Á¦¾à ¹°·ùÀÇ È¿À²¼ºÀÌ ÀúÇØµÉ ¼ö ÀÖ½À´Ï´Ù.
COVID-19ÀÇ ¿µÇâ
COVID-19 »çÅ·ΠÀÎÇØ ÀǾàǰ ½ÃÀå¿¡¼ ³Ãµ¿ ÄÁÅ×À̳ʿ¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çß½À´Ï´Ù. Àü ¼¼°è ¹é½Å À¯ÅëÀÇ ±ä±ÞÇÑ Çʿ伺°ú COVID-19 ¹é½Å ¹× ±âŸ ¿Âµµ¿¡ ¹Î°¨ÇÑ ÀǾàǰ¿¡ ´ëÇÑ ¾ö°ÝÇÑ ¿Âµµ ¿ä±¸ »çÇ×ÀÌ °áÇÕµÇ¾î ½Å·ÚÇÒ ¼ö ÀÖ´Â ÄݵåüÀÎ ¹°·ù¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇß½À´Ï´Ù. ÀÌ¿¡ µû¶ó Àü ¼¼°èÀûÀ¸·Î ÷´Ü ¸®ÆÛ ±â¼ú¿¡ ´ëÇÑ ÅõÀÚ°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, °ø±Þ¸Á ź·Â¼ºÀ» ³ôÀÌ°í ¿Âµµ º¯È¿¡ ¹Î°¨ÇÑ ÀǾàǰ ¹è¼ÛÀÇ ¹«°á¼ºÀ» º¸ÀåÇÏ´Â µ¥ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ´Éµ¿Çü ³Ã°¢ ½Ã½ºÅÛ ºÎ¹®ÀÌ °¡Àå Ŭ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¹é½Å ¹× »ý¹°ÇÐÀû Á¦Á¦¿Í °°Àº ¿Âµµ¿¡ ¹Î°¨ÇÑ Á¦Ç°ÀÇ È¿´ÉÀ» À¯ÁöÇϱâ À§ÇØ Á¤È®Çϰí Áö¼ÓÀûÀÎ ¿Âµµ °ü¸®°¡ ÇÊ¿äÇϱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È ¾×Ƽºê ³Ã°¢ ½Ã½ºÅÛ ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Éµ¿Çü ³Ã°¢Àº ƯÈ÷ Àå°Å¸® ¿î¼Û ¹× º¯µ¿ÀÌ ½ÉÇÑ È¯°æ Á¶°Ç¿¡¼ ¿î¼Û Áß ¾ÈÁ¤µÈ »óŸ¦ º¸ÀåÇÕ´Ï´Ù. Á¦¾à »ê¾÷¿¡¼ ¹ÙÀÌ¿ÀÀǾàǰ ¹× ¼¼°è À¯Åë¿¡ ´ëÇÑ °ü½ÉÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¾×Ƽºê ³Ã°¢ ½Ã½ºÅÛÀº ¾ö°ÝÇÑ ÄݵåüÀÎ ¿ä±¸ »çÇ× ¹× ±ÔÁ¦ Ç¥ÁØÀ» ÃæÁ·ÇÏ´Â µ¥ ÇʼöÀûÀÔ´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ¹°·ù Á¦°ø¾÷ü ºÎ¹®Àº °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È È¿À²ÀûÀÌ°í ¿Âµµ Á¶ÀýÀÌ °¡´ÉÇÑ ¿î¼Û ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ¹°·ù Á¦°ø¾÷ü ºÎ¹®ÀÌ °¡Àå ³ôÀº ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¼¼°è Á¦¾à ½ÃÀåÀÌ ¼ºÀåÇÔ¿¡ µû¶ó ¹°·ù ¾÷üµéÀº ¹é½Å ¹× »ý¹°ÇÐÀû Á¦Á¦¿Í °°Àº ¿Âµµ¿¡ ¹Î°¨ÇÑ Á¦Ç°ÀÇ ±î´Ù·Î¿î ¿ä±¸ »çÇ×À» ÃæÁ·Çϱâ À§ÇØ Ã·´Ü ÄݵåüÀÎ ±â¼ú¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. °ø±ÞÀÚ´Â Á¦Ç°ÀÇ ¹«°á¼º, ±ÔÁ¤ Áؼö ¹× Àû½Ã ¹è¼ÛÀ» º¸ÀåÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ´ã´çÇϰí ÀÖÀ¸¸ç, ÀÌ´Â Á¦¾à ¹°·ù¿¡¼ Àü¿ë ³Ãµ¿ ÄÁÅ×À̳ʿ¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ÀÇ·á, »ý¸í°øÇÐ, Á¦¾à ºÎ¹®ÀÇ ±Þ¼ÓÇÑ ¼ºÀåÀ¸·Î ÀÎÇØ ¾Æ½Ã¾ÆÅÂÆò¾çÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¹é½Å ¹× »ý¹°ÇÐÀû Á¦Á¦¿Í °°Àº ¿Âµµ¿¡ ¹Î°¨ÇÑ Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿Í Áß±¹ ¹× Àεµ¿Í °°Àº ±¹°¡¿¡¼ ÀǾàǰ »ý»êÀÌ È®´ëµÊ¿¡ µû¶ó ½Å·ÚÇÒ ¼ö ÀÖ´Â ÄݵåüÀÎ ¹°·ùÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÎÇÁ¶ó °³¹ß ¹× ±ÔÁ¦ °È´Â ÀÌ Áö¿ª Àüü¿¡¼ ¿Âµµ °ü¸® ¿î¼Û ¼Ö·ç¼ÇÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.
¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì´Â °¡Àå ³ôÀº CAGRÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ´Â ÀÌ Áö¿ªÀÇ °·ÂÇÑ ÀǾàǰ Á¦Á¶ ±â¹Ý°ú »ý¹°ÇÐÀû Á¦Á¦, ¹é½Å ¹× ±âŸ ¿Âµµ º¯È¿¡ ¹Î°¨ÇÑ ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, FDA¿Í °°Àº ¾ö°ÝÇÑ ±ÔÁ¦ Ç¥ÁØÀ¸·Î ÀÎÇØ ½Å·ÚÇÒ ¼ö ÀÖ´Â ÄݵåüÀÎ ¹°·ù°¡ ÇÊ¿äÇϱ⠶§¹®ÀÔ´Ï´Ù. ¶ÇÇÑ, ¹ÙÀÌ¿ÀÀǾàǰ¿¡ ´ëÇÑ °ü½É Áõ°¡, ±â¼ú ¹ßÀü, źźÇÑ À¯Åë¸ÁÀº °ø±Þ¸Á Àü¹Ý¿¡ °ÉÃÄ Á¦Ç°ÀÇ ¹«°á¼ºÀ» À¯ÁöÇϱâ À§ÇØ ³Ãµ¿ ÄÁÅ×À̳ʿ¡ ´ëÇÑ ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù.
According to Stratistics MRC, the Global Reefer Container for Pharmaceutical Market is accounted for $5.81 billion in 2024 and is expected to reach $10.36 billion by 2030 growing at a CAGR of 10.1% during the forecast period. A reefer container for pharmaceuticals is a specialized refrigerated shipping container designed to maintain a controlled temperature environment during the transportation of temperature-sensitive pharmaceutical products, such as vaccines, biologics, and certain medicines. These containers are equipped with advanced cooling systems to ensure that products remain within specific temperature ranges, preserving their efficacy and safety. Reefer containers play a critical role in cold-chain logistics, ensuring the integrity of pharmaceutical products from production facilities to distribution points across the world.
Rising demand for biopharmaceuticals
Biopharmaceutical products, such as monoclonal antibodies, gene therapies, and vaccines, require stringent temperature control to maintain their stability and efficacy. As these advanced therapies become more prevalent, especially in oncology and chronic disease management, the need for reliable cold chain logistics intensifies. Reefer containers are essential for transporting these sensitive products, ensuring that they remain within the required temperature range throughout their journey. This growing demand for biopharmaceuticals is fueling increased investments in temperature-controlled shipping solutions and reinforcing the importance of effective cold chain management.
Risk of temperature fluctuations
The quality and effectiveness of pharmaceutical products that are sensitive to temperature, such insulin, biologics, and vaccinations, can be jeopardized by even minor departures from the necessary temperature range. Temperature instability during transportation may be caused by elements such as equipment failure, insufficient insulation, or outside environmental circumstances. In order to guarantee accurate temperature management, this risk emphasizes the significance of sophisticated monitoring systems, routine maintenance, and real-time tracking. Reliable cold chain operations are crucial since any compromise in temperature integrity could lead to expensive product recalls, harm to a brand's reputation, and legal repercussions.
Growing awareness of cold chain logistics
Growing knowledge of cold chain logistics is a major factor propelling the pharmaceutical reefer container industry. Maintaining the integrity of medicines across the supply chain is of greater importance as the demand for temperature-sensitive medications, such as vaccines, biologics, and other biologically derived products, rises globally. Product degradation is avoided by maintaining temperature-sensitive items within specified ranges thanks to efficient cold chain management. The supply chain's overall efficiency and dependability have increased as a result of increased expenditures in reefer containers and temperature-controlled shipping options, as well as tighter regulations and consumer demand for safer, more dependable pharmaceutical products.
Limited availability of specialized containers
The pharmaceutical industry has a hurdle due to the restricted supply of specialized reefer containers, particularly as the need for temperature-controlled shipping grows. Standard refrigerated containers may not always be able to meet the highly specialized temperature and humidity requirements of pharmaceutical items, even though many reefer containers are made for universal usage. The effectiveness of pharmaceutical logistics might be hampered by supply chain bottlenecks, delays, and additional expenses caused by the lack of such specialized containers.
Covid-19 Impact
The COVID-19 pandemic significantly boosted the demand for reefer containers in the pharmaceutical market. The urgent need for global vaccine distribution, coupled with the stringent temperature requirements for COVID-19 vaccines and other temperature-sensitive pharmaceuticals, drove a surge in demand for reliable cold chain logistics. This led to increased investment in advanced reefer technologies, improved supply chain resilience, and a heightened focus on ensuring the integrity of temperature-sensitive pharmaceutical shipments worldwide.
The active cooling systems segment is expected to be the largest during the forecast period
The active cooling systems segment is expected to account for the largest market share during the forecast period, driven by the need for precise, continuous temperature control to maintain the efficacy of temperature-sensitive products like vaccines and biologics. Active cooling ensures stable conditions during transportation, especially over long distances or in fluctuating environmental conditions. As the pharmaceutical industry increasingly focuses on biopharmaceuticals and global distribution, active cooling systems are vital to meet stringent cold chain requirements and regulatory standards.
The logistics providers segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the logistics providers segment is predicted to witness the highest growth rate, due to the rising demand for efficient, temperature-controlled transportation solutions. As the global pharmaceutical market grows, logistics companies are investing in advanced cold-chain technologies to meet the stringent requirements for temperature-sensitive products like vaccines and biologics. Providers play a critical role in ensuring product integrity, regulatory compliance, and timely delivery, driving the demand for specialized reefer containers in pharmaceutical logistics.
During the forecast period, Asia Pacific region is expected to hold the largest market share, due to rapid growth in healthcare, biotechnology, and pharmaceutical sectors. The increasing demand for temperature-sensitive products like vaccines and biologics, along with expanding pharmaceutical production in countries like China and India, has fueled the need for reliable cold-chain logistics. Enhanced infrastructure and regulatory developments further support the growth of temperature-controlled shipping solutions across the region.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to the region's strong pharmaceutical manufacturing base and growing demand for biologics, vaccines, and other temperature-sensitive drugs. Strict regulatory standards, such as those from the FDA, ensure the need for reliable cold chain logistics. Additionally, the increasing focus on biopharmaceuticals, advancements in technology, and robust distribution networks are further boosting the demand for reefer containers to maintain product integrity throughout the supply chain.
Key players in the market
Some of the key players profiled in the Reefer Container for Pharmaceutical Market include Maersk Line, CMA CGM Group, MSC Mediterranean Shipping Company, Hapag-Lloyd, Evergreen Marine Corporation, AP Moller-Maersk, ZIM Integrated Shipping Services, Kuehne + Nagel, China COSCO Shipping Corporation, DP World, Seaco Global, DHL Supply Chain, United Arab Shipping Company (UASC), Cool Containers, and Geodis Logistics.
In September 2024, Maersk and Hapag-Lloyd announced their "Gemini Cooperation" to start in 2025 that would further improve the reliability of services and increase capacity by jointly operating a combined fleet of 290 vessels. It will underpin global trade routes, including those vital for pharmaceuticals.
In July 2024, MEDLOG, the logistics arm of MSC, has ceremoniously marked the start of construction of a 291,000 square foot state-of-the-art cold storage facility in Savannah, Georgia. The project is to symbolically signal a key addition to the export capability of poultry, pork and meat producers from the USA Southeast and Midwest.